301301.SZ
301301.SZ
CNE100005WX0
CN BIO
Loading chart...

Company Profile

Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. It offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; ursodeoxycholic acid; coenzyme Q10 mycelia; and other products. It also provides synthetic biology products, including bisabolol, 5-hydroxytryptophan, ergothioneine, ectoine, inositol, squalane, polyhydroxyalkanoate (PHA), and phytosphingosine. In addition, the company engages in trading, crop cultivation, detection, technical consultation, and asset investment activities. The company was incorporated in 2010 and is based in Yining, China. Yili Chuanning Biotechnology Co.,Ltd. operates as a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.

Related stocks

9606.HK
9606.HK • China
DUALITYBIO-B
182.7 HKD
2.13B USD 1Y -42.1%
2162.HK
2162.HK • China
KEYMED BIO-B
78.3 HKD
2.94B USD 1Y +9.9%
2315.HK
2315.HK • China
BIOCYTOGEN-B
69.2 HKD
3.91B USD 1Y +170.7%
688278.SS
688278.SS • China
XIAMEN AMOYTOP BIOTECH CO LTD
50.77 CNY
3.1B USD 1Y -37.6%
688166.SS
688166.SS • China
BRIGHTGENE BIO-MEDICAL TECHNOLO
33.53 CNY
2.19B USD 1Y -41.8%
300255.SZ
300255.SZ • China
CHANGSHAN PHARMA
22.15 CNY
3.05B USD 1Y -55.1%
9969.HK
9969.HK • China
INNOCARE
12.73 HKD
2.87B USD 1Y -23.4%
688266.SS
688266.SS • China
SUZHOU ZELGEN BIOPHARMACEUTICAL
104.25 CNY
4.13B USD 1Y -2.2%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
42.9% p.a.
Max Drawdown (5Y)
-55.5%
Sharpe Ratio (5Y)
-0.18
Beta Factor
0.02
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (42.9% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -55.5% in the extended horizon.
ende